Jeffrey M. Leiden - 17 Feb 2026 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
Executive Chairman, Director
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
17 Feb 2026
Net transactions value
-$1,433,835
Form type
4
Filing time
19 Feb 2026, 16:18:51 UTC
Previous filing
26 Jan 2026
Next filing
26 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
LEIDEN JEFFREY M Executive Chairman, Director C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON /s/ Christiana Stevenson, Attorney-in-Fact 19 Feb 2026 0001242825

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Award $0 +8,269 +25% $0.000000 41,308 17 Feb 2026 Direct F1
transaction VRTX Common Stock Tax liability $1,433,835 -2,964 -7.2% $483.75 38,344 18 Feb 2026 Direct
holding VRTX Common Stock 440 17 Feb 2026 401(k)
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock unit award that fully vested upon grant.